Serum Multimarkers Assay based Rapid Test (SMART) for Systemic lupus erythematosus

基于血清多标志物检测的系统性红斑狼疮快速检测 (SMART)

• 批准号: 8905850
• 负责人: John Collins
• 金额: $ 22.39万
• 依托单位: BIOPICO
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-06-01 至 2017-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8905850
• 关键词: Address; Adhesives; Affect; Age; American; Antibodies; Antigens; Area Under Curve; Asses; Benchmarking; Binding; Biochemical; Biological Assay; Biological Markers; Blood; Blood specimen; Calibration; California; Characteristics; Clinical; Clinical Management; Clinical Trials; Complex; Computer software; Coupled; Detection; Development; Devices; Diagnosis; Diagnostic; Disease; Disease remission; Early Diagnosis; Electrodes; Electroplating; Enzyme-Linked Immunosorbent Assay; Evaluation; Family-Based Registry; Flare; Gender; Gold; Human; Immunoassay; Injection of therapeutic agent; Inorganic Sulfates; Institutes; Intervention; Label; Laboratories; Lupus; Lupus Coagulation Inhibitor; Marketing; Measurement; Measures; Microfluidics; Molds; Nanostructures; Nickel; Outcome; Patient Monitoring; Patients; Pattern; Performance; Phase; Physiologic pulse; Point-of-Care Systems; Printing; Process; Proteins; Protocols documentation; Quality of life; Reaction; Receiver Operating Characteristics; Relaxation; Research; Sampling; Sensitivity and Specificity; Serum; Serum Markers; Services; Severities; Site; Specificity; Staging; Subgroup; Symptoms; System; Systemic Lupus Erythematosus; Technical Expertise; Techniques; Technology; Testing; Time; Universities; Unspecified or Sulfate Ion Sulfates; Validation; Variant; Vision; Whole Blood; base; clinical application; clinical care; cost; data acquisition; density; design; diagnostic accuracy; drug development; electric impedance; fascinate; high throughput screening; human disease; improved; micro-total analysis system; miniaturize; nanoengineering; nanosensors; nanostructured; novel; operation; personalized medicine; point of care; portability; public health relevance; repository; research and development; research study; response; screening; sensor; tool; true biomarker; user-friendly; wasting

 DESCRIPTION (provided by applicant): Serum Multimarkers Assay Based Rapid Test (SMART) for Systemic Lupus Erythematosus Measurement of panels of biomarker proteins from whole blood holds great promise for early detection of diseases, guidance to personalized therapy, and drug development. For broad clinical applicability, new devices are needed that offer high portability, low cost, high sensitivity and accuracy, automatic operation and require minimal technical expertise. In this regard, micro/nano engineering techniques such as lab-on-a-chip technologies and nanosensors are emerging as the next revolution tools for this unrealized promise of user-friendly quantitative multiplexed diagnostics for candidate biomarkers. Such advantages can be integrated in ELISA based assay with an electrically recordable format for the measurement of serum biomarkers from whole blood for complex diseases such as Systemic Lupus Erythematosus (SLE). The clinical management of the multifaceted diseases is tampered by variation of clinical symptoms, unsteady flares and remissions, unpredictable severity and absence of true biomarkers which demand multiple biomarker signatures to reflect all aspects of SLE. Further, point-of-care analyses are preferred over off-site determinations, posing an even more formidable bioanalytical challenge. So there is an urgent need for the development of low cost, reliable and portable devices with less human intervention for the multimarker diagnostics of SLE. Therefore Biopico Systems Inc. teams with University of California, Irvine to bring out a truly revolutionary Serum Multimarkers Assay based Rapid Test (SMART) using microfluidic serum extraction from whole blood and multiplexed sensing using nanosensor array. This SMART system will enable laboratory analysis for faster, direct, accurate and selective for a wide variety of diseases panel and so has the potential to be miniaturized and integrated as a user-friendly point of care system for patients undergoing therapy. The influence of racial background, age, gender and disease stage on experimental outcome among large number of patients' samples will be statistically analyzed to establish expression pattern and percent association of the candidate biomarkers of SLE.

 描述（应用程序提供）：基于全身性红斑狼疮的基于血清的快速测试（SMART）测量全血的生物标志物蛋白的测量，这是对疾病的早期发现，个性化疗法的指导和药物开发的巨大希望。对于广泛的临床适用性，需要新的设备，以提供高便携性，低成本，高灵敏度和准确性，自动操作，并且需要最少的技术专业知识。在这方面，微/纳米工程技术（例如实验室芯片技术和纳米传感器）正在成为这种未实现的候选生物标志物的无友好定量多重诊断的未实现的诺言工具。这些优点可以与电子记录的格式集成到基于ELISA的测定中，以测量全身性疾病（例如全身性狼疮红膜（SLE））的血清生物标志物（SLE）。多面疾病的临床管理被临床症状，不稳定的耀斑和缓解，不可预测的严重程度以及缺乏真正的生物标志物的变化所篡改，这些物种需要多个生物标志物特征来反映SLE的所有方面。此外，与现场确定相比，预处点分析是优选的，带来了更强大的生物分析挑战。因此，迫切需要开发低成本，可靠和便携式设备，对SLE的多标志物诊断进行了较少的人力干预。因此，使用纳米传感器阵列从全血和多路复用感应中提取微流体血清提取基于纳米传感的微流体血清提取，因此与加利福尼亚大学尔湾分校的加利福尼亚大学的团队一起，基于基于革命性的血清多标记测定快速测试（SMART）。该智能系统将使实验室分析能够更快，直接，准确和有选择性，以适应各种疾病面板，因此有可能将小型化并整合为接受治疗患者的用户友好的护理系统。种族背景，年龄，性别和疾病阶段对大量患者样本的实验结果的影响将经过统计分析，以建立SLE候选生物标志物的表达模式和百分比。